Rockwell Medical Adds 30 New Customers in the West

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Neutral)

Key Terms

hemodialysis medical

Hemodialysis is a medical treatment that cleans a person’s blood when their kidneys can no longer do the job, by routing blood through a machine that filters out waste, excess fluid and adjusts salt levels—think of it as an external, mechanical kidney. It matters to investors because it drives demand for specialized machines, replacement filters, clinics, trained staff and related drugs, and is sensitive to reimbursement rules, treatment volumes and advances that can change costs or market share.

hemodialysis concentrates medical

Hemodialysis concentrates are concentrated liquid or powder mixtures that are mixed with water to produce the cleansing fluid used in hemodialysis treatments; they contain salts and other ingredients that help remove waste and balance electrolytes in a patient’s blood. For investors, these concentrates are a critical recurring consumable: their supply, price, quality and regulatory status can affect clinic operating costs, treatment continuity and revenue, much like how a soda syrup concentrate determines cost and availability at a fountain.

end-stage kidney disease medical

A permanent, irreversible loss of normal kidney function so the body can no longer reliably filter waste and balance fluids without medical intervention, typically managed with regular dialysis or a kidney transplant. Investors watch it because it creates a steady, long-term demand for drugs, devices, treatment services and insurance spending — similar to a fleet of vehicles that require constant repairs or replacement, producing predictable recurring revenue opportunities.

artificial kidney medical

An artificial kidney is a medical device that performs the blood-filtering and fluid-balancing work of a failing human kidney, either as an external machine, a wearable system, or an implanted device—think of it as a portable water filter for the bloodstream. Investors care because it targets a large, chronic-illness market with high ongoing treatment costs; successful devices can reduce healthcare spending, win long-term contracts and reimbursement, and create significant growth if they clear safety and regulatory hurdles.

01/12/2026 - 06:00 AM

The Company generates multi-million dollars in revenue with new west coast customer base

The Western U.S. now accounts for more than 10% of the Company's customer clinic footprint

WIXOM, Mich.--(BUSINESS WIRE)-- Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company has added 30 new customers in the western portion of the United States.

"Over the past several months, the hemodialysis concentrates supply chain has experienced meaningful disruption, particularly in the western United States," said Mark Strobeck, Ph.D., President and CEO of Rockwell Medical. "Historically, hemodialysis concentrates supplier options in the west have been extremely limited. To stabilize the supply chain and ensure uninterrupted access to life-sustaining treatments for vulnerable patients with end-stage kidney disease, Rockwell Medical moved quickly to ensure product availability by rapidly scaling production and expanding our logistics infrastructure to address vital customer demand. As a result, we are now serving customers across the continental United States with our reliable supply chain and high-quality hemodialysis products."

The Company’s new customer base includes, but is not limited to, a large, integrated, non-profit healthcare system; a comprehensive chronic kidney disease and dialysis care organization serving patients throughout California; a community-based, non-profit acute care hospital; and an innovation-driven renal care center developing and delivering next-generation artificial kidney solutions. With its expanded distribution capabilities, Rockwell Medical is now a viable alternative supplier in the western United States and is able to more efficiently deliver hemodialysis concentrates products to its existing customers with facilities in that region.

About Rockwell Medical

Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. Rockwell Medical's mission is to provide dialysis clinics and the patients they serve with the highest quality products supported by the best customer service in the industry. Rockwell is focused on innovative, long-term growth strategies that enhance its products, its processes, and its people, enabling the Company to deliver exceptional value to the healthcare system and provide a positive impact on the lives of hemodialysis patients. Hemodialysis is the most common form of end-stage kidney disease treatment and is typically performed in freestanding outpatient dialysis centers, hospital-based outpatient centers, skilled nursing facilities, or a patient’s home. Rockwell Medical's products are vital to vulnerable patients with end-stage kidney disease, and the Company is relentless in providing unmatched reliability and customer service. Certified as a Great Place to Work^® in 2023, 2024 and 2025, and named Fortune Best Workplaces in Manufacturing & Production™ in 2024 and 2025, Rockwell Medical is Driven to Deliver Life-Sustaining Dialysis Solutions™. For more information, visit www.rockwellmed.com.

Forward-Looking Statements

Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as, "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "could," "can," "would," "develop," "plan," "potential," "predict," "forecast," "project," "intend," "look forward to," "remain confident," “are determined,” “are committed to,” “are on track,” “are resolute in our vision,” "work to," "drive towards," “focused on,” “seeks to” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical's SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include, but are not limited to those risks more fully discussed in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2024, as such description may be amended or updated in any future reports we file with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law.